FDA Grants Fast Track designation to IVS-3001, a CAR-T Cell Therapy in the Treatment of Renal Cell Carcinoma Houston, TX, USA, July 31, 2023 (GLOBE NEWSWIRE) -- Invectys, Inc., a clinical-stage immuno-oncology company focused on developing novel therapies for advanced cancers, is pleased to announce the...